Clinuvel Pharmaceuticals Full Year 2025 Earnings: Misses Expectations

Clinuvel Pharmaceuticals (ASX:CUV) Full Year 2025 Results

Key Financial Results

• Revenue: AU$95.0m (up 7.8% from FY 2024).
• Net income: AU$36.2m (up 1.5% from FY 2024).
• Profit margin: 38% (down from 40% in FY 2024). The decrease in margin was driven by higher expenses.
• EPS: AU$0.72 (up from AU$0.71 in FY 2024).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Clinuvel Pharmaceuticals Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) also missed analyst estimates by 8.2%.

The primary driver behind last 12 months revenue was the Europe & USA Excl. Switzerland segment contributing a total revenue of AU$86.7m (91% of total revenue). The largest operating expense was General & Administrative costs, amounting to AU$32.2m (64% of total expenses). Explore how CUV's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Biotechs industry in Australia.

Performance of the Australian Biotechs industry.

The company's shares are down 18% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. See our latest analysis on Clinuvel Pharmaceuticals' balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.